European Society for Medical Oncology (ESMO) 2019 Congress

Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.

Adding the PD-L1 inhibitor atezolizumab to first-line platinum-based chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic urothelial carcinoma (mUC), according to the IMvigor130* study presented at the ESMO Congress 2019.

The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.

Podcast: Dr Susana Benerjee says more women should be getting PARP inhibitors in the first-line setting

Podcast: Dr Peter Schmid on why KEYNOTE-522 has the potential to be a practice-changing trial

Podcast: Dr Maha Hussain highlights the relevance of molecularly targeted therapies in Asians with mCRPC in PROfound

Podcast: Dr Dennis Slamon says MONALEESA-3 supports the potential of CDK4/6 inhibitors in the first-line setting for HR+/HER2- breast cancer

Podcast: Associate Prof Pilar Garrido says FLAURA supports osimertinib as the new standard of care for EGFR-mutant advanced NSCLC

Podcast: Dr Marina Garassino brings context to the CheckMate 227 analysis of NIVO + IPI in advanced NSCLC